文献速递支持与姑息治疗

肌酸治疗癌症厌食/体重减轻综合征的双盲安慰剂对照随机试验(N02C4):一项Alliance试验

A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial.
PubMed 文献 · Ann Oncol · 2017-01-01

这项随机双盲安慰剂对照试验纳入263例不可治愈的癌症厌食/体重减轻综合征患者,分别接受肌酸(先20 g/天负荷5天,后2 g/天口服)或安慰剂。主要终点为第一个月内体重较基线增加≥10%,肌酸组仅2例、安慰剂组1例达到(P=1.00)。食欲、生活质量、握力、体成分及不良事件组间均无统计学显著差异,中位生存期肌酸组230天 vs 安慰剂组239天(P=0.70)。

要点

  • 肌酸组仅2例、安慰剂组1例在1个月内体重较基线增加≥10%(P=1.00)。
  • 食欲、生活质量、日常生活活动、握力及体成分组间均无统计学显著差异。
  • 两组不良事件发生率和严重程度相当;中位生存期230天 vs 239天(P=0.70)。

核心结论

  • 按本试验所给方案使用肌酸,对癌症厌食/体重减轻综合征无效果。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,纳入不可治愈的癌症厌食/体重减轻综合征患者,肌酸组134例、安慰剂组129例,共263例可评估患者。
  • 肌酸给药方案为20 g/天负荷5天,随后2 g/天口服;对照组给予相同外观的安慰剂。
  • 患者每周称重1次持续1个月,之后每月称重;并在1个月内评估食欲、生活质量(经验证问卷)、握力、体成分(生物电阻抗)及不良事件。
  • 主要终点为第一个月内体重较基线增加≥10%。

主要发现

  • 263例可评估患者中仅3例在1个月内体重较基线增加≥10%:肌酸组2例、安慰剂组1例(P=1.00)。
  • 食欲、生活质量及日常生活活动问卷数据组间无统计学显著差异。
  • 握力和体成分组间亦无统计学显著差异。
  • 不良事件发生率和严重程度组间相当。
  • 肌酸组和安慰剂组中位生存期分别为230天和239天(P=0.70)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple pilot studies, including one in colorectal cancer patients, suggest that creatine, an amino acid derivative, augments muscle, improves strength, and thereby could palliate the cancer anorexia/weight loss syndrome. PATIENTS AND METHODS: In this randomized, double-blind, placebo-controlled trial, incurable patients with this syndrome were assigned creatine (20 g/day load×5 days followed by 2 g/day orally) versus identical placebo. Patients were weighed once a week for 1 month and then monthly. Patients were also assessed over 1 month for appetite and quality of life (validated questionnaires), fist grip strength, body composition (bioelectrical impedance), and adverse events. The primary endpoint was 10% or greater weight gain from baseline during the first month. RESULTS: Within this combined cohort of 263 evaluable patients (134 received creatine and 129 placebo), only 3 gained ≥10% of their baseline weight by 1 month: two creatine-treated and the other placebo-exposed (P = 1.00). Questionnaire data on appetite, quality of life, and activities of daily living showed no statistically significant differences between groups. Similarly, no statistically significant differences between groups were observed for fist-grip strength or body composition. Rates and severity of adverse events were comparable between groups. Finally, a median survival of 230 and 239 days were observed in the creatine and placebo groups, respectively (P = 0.70). CONCLUSION: Creatine, as prescribed in this trial, had no effect on the cancer anorexia/weight loss syndrome.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Jatoi A, Steen PD, Atherton PJ, et al. A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial. Ann Oncol. 2017. PMID: 28475678. doi:10.1093/annonc/mdx232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。